Scinai Immunotherapeutics Regains Nasdaq Compliance, Clearing Delisting Risk

Key Facts

1Nasdaq confirmed Scinai Immunotherapeutics regained compliance with Listing Rule 5550(a)(2) after its closing bid price remained at or above $1.00 for 19 consecutive business days.

In a move that underscores the importance of regulatory stability for micro-cap firms, Scinai Immunotherapeutics has officially regained compliance with Nasdaq’s listing requirements. According to reports, Nasdaq confirmed the company satisfied Listing Rule 5550(a)(2) after its closing bid price remained at or above $1.56 for 19 consecutive business days. This development officially closes the deficiency matter, removing the immediate threat of delisting that had previously shadowed the biopharmaceutical firm.

The resolution of this compliance issue provides a significant milestone for the company's market standing, as maintaining a listing on a major exchange is critical for institutional visibility and liquidity. Per market data, the stock's ability to hold the $1.56 threshold reflects a stabilization in investor sentiment following the initial notification of non-compliance. This regulatory clearance allows management to shift focus back toward its core therapeutic development and manufacturing operations.

As of the close on September 18, 2026, SCNI was priced at $1.56, having traded within a daily range of $1.50 to $1.77. While the economic calendar shows no upcoming corporate catalysts for the next seven days, market participants will likely watch the $1.56 support level to ensure the stock maintains its newly regained compliance status in the long term.